GSK has announced positive opinions from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of two new potential medicines for respiratory diseases. Depemokimab has been recommended as add-on maintenance treatment for severe asthma with type 2 inflammation (12+) and as an add-on therapy with intranasal corticosteroids for […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!